The Medicines Company sells rights to Cleviprex (clevidipine), Kengreal (cangrelor) and the rights to Argatroban for Injection to Chiesi USA, Inc.
The Medicines Company announced that it has entered into a definitive agreement to sell Cleviprex (clevidipine), Kengreal (cangrelor) and the Company�s rights to Argatroban for Injection to Chiesi USA, Inc. and its parent company, Chiesi Farmaceutici S.p.A., for up to $792 million, consisting of $260 million in cash payable at closing, up to $480 million in sales-based milestone payments, the assumption by Chiesi of up to $50 million in milestone payment obligations and approximately $2 million for product inventory.
Comment: The Medicines Group leading product Angiomax (bivalirudin) lost patent protection in July 2015 and now faces generic competition with a fall in sales from $100.7 million to $16.9 million for first quarter sales.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins